Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study.

Abstract:

:The potential interaction between chronic hepatitis B (CHB) and nonalcoholic fatty liver disease (NAFLD), two of the most prevalent liver diseases worldwide, has not been well defined. We performed liver stiffness (LS) and controlled attenuation parameter (CAP) measurements using transient elastography in 1202 CHB patients. Of these, 601 steatotic patients were matched with nonsteatotic controls in a 1:1 ratio by age, gender, nucleoside analogue treatment status, and treatment duration. Severe fibrosis was defined according to EASL-ALEH criteria, and steatosis was defined as CAP ≥222 dB m-1 . Anthropometric measurements and metabolic-related parameters were recorded. The mean age of the 1202 patients (51.4% male) was 51.8 years. 696 patients (57.9%) were on nucleoside analogues for a median duration of 76.2 months. Among treatment-naïve patients, median serum HBV DNA was lower in steatotic individuals than in controls (3.0 vs 3.4 log IU mL-1 , P < .05), with this inverse relationship remaining significant in multivariate analysis (odds ratio 0.859, 95% CI 0.743-0.994, P < .05). With increased steatosis severity, there was a stepwise decrease in median HBV DNA levels (3.1 and 2.6 log IU mL-1 in no steatosis and severe steatosis, respectively, P = .032). Steatosis was associated with a higher median LS (5.4 kPa vs 5.0 kPa, P < .001). Severe steatosis, when compared to mild/moderate steatosis, was associated with an increased percentage of severe fibrosis (23.2% and 12.6%, respectively, P = .005). We conclude that severe steatosis was associated with increased fibrosis in CHB patients. Increasing steatosis was independently associated with lower serum HBV DNA levels, suggesting its potential negative effects on viral replication.

journal_name

J Viral Hepat

authors

Hui RWH,Seto WK,Cheung KS,Mak LY,Liu KSH,Fung J,Wong DK,Lai CL,Yuen MF

doi

10.1111/jvh.12766

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

97-104

issue

1

eissn

1352-0504

issn

1365-2893

journal_volume

25

pub_type

杂志文章
  • Occult hepatitis C virus infection in type II mixed cryoglobulinaemia.

    abstract::Mixed cryoglobulinaemia, when not secondary to other well-defined immunological disorders, is commonly associated with hepatitis C virus (HCV) infection. However, a minority of cases lack evidence of HCV infection and are, therefore, defined as 'true essential' mixed cryoglobulinaemias. We thoroughly investigated thre...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00462.x

    authors: Casato M,Lilli D,Donato G,Granata M,Conti V,Del Giudice G,Rivanera D,Scagnolari C,Antonelli G,Fiorilli M

    更新日期:2003-11-01 00:00:00

  • Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.

    abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2010.01332.x

    authors: Moucari R,Boyer N,Ripault MP,Castelnau C,Mackiewicz V,Dauvergne A,Valla D,Vidaud M,Chanoine MH,Marcellin P

    更新日期:2011-08-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

    abstract::Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 20...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12351

    authors: Hatzakis A,Chulanov V,Gadano AC,Bergin C,Ben-Ari Z,Mossong J,Schréter I,Baatarkhuu O,Acharya S,Aho I,Anand AC,Andersson MI,Arendt V,Arkkila P,Barclay K,Bessone F,Blach S,Blokhina N,Brunton CR,Choudhuri G,Cisneros

    更新日期:2015-01-01 00:00:00

  • An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.

    abstract::Single nucleotide polymorphisms (SNPs) in the interleukin 28B gene (IL28B) are good pretreatment predictors of anti-hepatitis C virus (HCV) therapy with interferon. SNPs of the inosine triphosphatase (ITPA) gene are associated with reduced haemoglobin levels during treatment with ribavirin. The i-densy™ (Arkray, Inc.)...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12026

    authors: Takahashi H,Mizuta T,Oeda S,Isoda H,Nakashita S,Kawaguchi Y,Izumi N,Hirai M,Kurose K,Iwane S,Eguchi Y,Kimura S,Anzai K,Ozaki I

    更新日期:2013-04-01 00:00:00

  • The association of HIV viral load with indirect markers of liver injury.

    abstract::This study assessed the association of HIV RNA with indirect markers of liver injury including FIB-4 index, liver enzymes and platelet counts in a high-risk Hispanic population. The data were derived from a prospective study that included 138 HIV/hepatitis C (HCV)-coinfected and 68 HIV-infected participants without he...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01529.x

    authors: Forrester JE,Rhee MS,McGovern BH,Sterling RK,Knox TA,Terrin N

    更新日期:2012-02-01 00:00:00

  • Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

    abstract::This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients. These fiftee...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.1996.tb00094.x

    authors: Rasi G,Mutchnick MG,Di Virgilio D,Sinibaldi-Vallebona P,Pierimarchi P,Colella F,Favalli C,Garaci E

    更新日期:1996-07-01 00:00:00

  • Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.

    abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01486.x

    authors: Togo S,Arai M,Tawada A,Chiba T,Kanda T,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2011-10-01 00:00:00

  • Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.

    abstract::Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-effectiveness of a Médecins Sans Frontières (MSF) HCV screening and treatment programme within a primary health clinic in Karachi, Pak...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13422

    authors: Mafirakureva N,Lim AG,Khalid GG,Aslam K,Campbell L,Zahid H,Van den Bergh R,Falq G,Fortas C,Wailly Y,Auat R,Donchuk D,Loarec A,Coast J,Vickerman P,Walker JG

    更新日期:2021-02-01 00:00:00

  • Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

    abstract::Liver damage may result from multiple factors in HIV-infected patients. The availability of reliable noninvasive tools to measure liver fibrosis has permitted the screening of large patient populations. Cross-sectional study of all consecutive HIV outpatients who underwent examination by transient elastometry (FibroSc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01261.x

    authors: Blanco F,Barreiro P,Ryan P,Vispo E,Martín-Carbonero L,Tuma P,Labarga P,Medrano J,González-Lahoz J,Soriano V

    更新日期:2011-01-01 00:00:00

  • Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

    abstract::A simple, pangenotypic and effective treatment regimen for patients with a broad range of chronic hepatitis C virus (HCV) infections remains an unmet medical need. We conducted a phase 2, randomized, open study involving untreated patients with chronic HCV genotypes 1, 2, 3, or 6 infections. Patients without cirrhosis...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13208

    authors: Rao H,Song G,Li G,Yang Y,Wu X,Guan Y,Mao Q,Jiang X,Wang C,Zhang Y,Jia J,Guo X,Li C,Ning J,Qin H,Pan H,Wei L

    更新日期:2020-01-01 00:00:00

  • What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

    abstract::Summary.  Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Bo...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01613.x

    authors: Ahmed F

    更新日期:2013-05-01 00:00:00

  • Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

    abstract::Chronic hepatitis C virus (HCV) infection eventually leads to cirrhosis in 20-30% of patients and to hepatocellular carcinoma (HCC) in 1-5% of patients. Rates of sustained virological response with standard interferon-alpha (IFN-alpha) are low in patients without cirrhosis (generally < 20%) and are even lower in those...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00229.x

    authors: Zeuzem S

    更新日期:2000-09-01 00:00:00

  • Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.

    abstract::The aim of this study was to evaluate the pharmacokinetic profile of daclatasvir (DCV) and asunaprevir (ASV) dual therapy in haemodialysis patients infected with hepatitis C virus (HCV). Eighteen haemodialysis patients and 54 patients with normal renal function were treated with DCV and ASV dual therapy for 24 weeks. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12553

    authors: Kawakami Y,Imamura M,Ikeda H,Suzuki M,Arataki K,Moriishi M,Mori N,Kokoroishi K,Katamura Y,Ezaki T,Ueno T,Ide K,Masaki T,Ohdan H,Chayama K

    更新日期:2016-11-01 00:00:00

  • Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

    abstract::We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV-, HIV-HBV- and HBV-infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV-infected patients, 85 HIV-HBV-coinfected patients and 50 HBV-infected...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12088

    authors: Pradat P,Le Pogam MA,Okon JB,Trolliet P,Miailhes P,Brochier C,Maynard M,Bailly F,Zoulim F,Cotte L

    更新日期:2013-09-01 00:00:00

  • Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.

    abstract::The prevalence of chronic hepatitis C virus (HCV) and the presence of human pegivirus 2 (HPgV-2) have not been examined in Cameroon, although HCV has been associated with HPgV-2 infections previously. Herein we aimed to characterize the burden and genetic diversity of HCV and the presence of HPgV-2 in Cameroon. Retros...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12996

    authors: Rodgers MA,Holzmayer V,Vallari A,Olivo A,Forberg K,Fuhrman J,Coller KE,Awazi B,Kenmegne Sidje JB,Frankel MB,Berg MG,Mbanya D,Ndembi N,Cloherty GA

    更新日期:2019-01-01 00:00:00

  • Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.

    abstract::Patients with biopsy-proven chronic hepatitis C, who failed to respond to a previous course of either recombinant (rIFN-alpha) or lymphoblastoid (Ly IFN-alpha) interferon-alpha, were randomized to receive either leucocyte (Le) IFN-alpha (patients) or a second course of the same IFN-alpha (controls), to compare the eff...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.1997.00146.x

    authors: Gaeta GB,Di Virgilio D,Russo G,Stornaiuolo G,Nicolella U,Colella F,Grimaldi M,Pasquale G,Giusti G

    更新日期:1997-05-01 00:00:00

  • Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

    abstract::Chronic hepatitis C infection leads to increased hepatocyte apoptosis. Because engulfment of apoptotic bodies (ABs) by hepatic stellate cells (HSC) is profibrogenic, we compared the effects of ABs derived from hepatitis C virus (HCV)-negative vs HCV-infected (Con1+) Huh7 hepatoblastoma cells on fibrogenic and activati...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01362.x

    authors: Gieseler RK,Marquitan G,Schlattjan M,Sowa JP,Bechmann LP,Timm J,Roggendorf M,Gerken G,Friedman SL,Canbay A

    更新日期:2011-11-01 00:00:00

  • Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection.

    abstract::Previously, we have determined that human annexin V (hAV), a Ca2+-dependent phospholipid-binding protein, and not rat AV, binds specifically to small hepatitis B surface antigen (SHBsAg), and that transfection of a rat hepatoma cell line with a construct containing the hAV gene led to hAV expression and conferred susc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2000.00207.x

    authors: De Meyer S,Gong ZJ,Hertogs K,Depla E,van Pelt JF,Roskams T,Maertens G,Yap SH

    更新日期:2000-03-01 00:00:00

  • Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider.

    abstract::Hepatitis delta virus (HDV) is a serious cause of liver-related morbidity and mortality. Coexistent infection with HDV tends to aggravate the course of hepatitis B virus (HBV)-associated liver disease. The aim of this study was to determine the prevalence of HDV infection among patients chronically infected with HBV i...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01329.x

    authors: Bahcecioglu IH,Aygun C,Gozel N,Poyrazoglu OK,Bulut Y,Yalniz M

    更新日期:2011-07-01 00:00:00

  • Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.

    abstract::The aim of this study was to evaluate the Chiron branched DNA (bDNA) assay for detection of serum hepatitis B virus (HBV) DNA in patients with chronic hepatitis B lacking hepatitis B e antigen (HBeAg) and undergoing interferon (IFN) therapy. Results obtained with the bDNA assay were compared with those obtained using ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00128.x

    authors: Habersetzer F,Zoulim F,Jusot JF,Zhang X,Trabaud MA,Chevallier P,Chevallier M,Ahmed SN,Sepetjan M,Comanor L,Minor J,Trépo C

    更新日期:1998-11-01 00:00:00

  • Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

    abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2005.00682.x

    authors: Bräu N,Bini EJ,Currie S,Shen H,Schmidt WN,King PD,Ho SB,Cheung RC,Hu KQ,Anand BS,Simon FR,Aytaman A,Johnson DP,Awad JA,Ahmad J,Mendenhall CL,Pedrosa MC,Moseley RH,Hagedorn CH,Waters B,Chang KM,Morgan TR,Rossi

    更新日期:2006-04-01 00:00:00

  • Acute hepatitis A in Italy: incidence, risk factors and preventive measures.

    abstract::The incidence of, and risk factors for, acute hepatitis A (AHA) were assessed by using data collected from the Italian surveillance system of acute viral hepatitis (SEIEVA). To this end, a case-control study within a population-based surveillance for acute viral hepatitis was performed. AHA incidence has been estimate...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01025.x

    authors: Tosti ME,Spada E,Romanò L,Zanetti A,Mele A,SEIEVA collaborating group.

    更新日期:2008-10-01 00:00:00

  • Expression of interferon-alpha subtypes in peripheral mononuclear cells from patients with chronic hepatitis C: a role for interferon-alpha5.

    abstract::Interferon (IFN)-alpha is a family of antiviral proteins encoded by different genes. The biological significance of the existence of various IFN-alpha subtypes is not clear. We have investigated the interferon system in chronic hepatitis C virus (HCV) infection, a disease that responds to interferon-alpha2 therapy in ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00273.x

    authors: Larrea E,Alberdi A,Castelruiz Y,Boya P,Civeira MP,Prieto J

    更新日期:2001-03-01 00:00:00

  • Autoantibodies in chronic hepatitis C virus infection and their association with disease profile.

    abstract::Autoantibodies are commonly detected in chronic hepatitis C (HCV) but their significance remains uncertain. We assessed the prevalence of anti-nuclear (ANA) and anti-smooth muscle (ASM) antibodies within a cohort of 963 treatment-naïve HCV patients. We also assessed for differences between autoantibody-positive and au...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01035.x

    authors: Williams MJ,Lawson A,Neal KR,Ryder SD,Irving WL,Trent HCV Group.

    更新日期:2009-05-01 00:00:00

  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    abstract:SUMMARY:Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE and FIBROSpect II) during interfer...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2008.01062.x

    authors: Patel K,Benhamou Y,Yoshida EM,Kaita KD,Zeuzem S,Torbenson M,Pulkstenis E,Subramanian GM,McHutchison JG

    更新日期:2009-03-01 00:00:00

  • Hepatitis C is more severe in drug users with human immunodeficiency virus infection.

    abstract::Drug users with chronic hepatitis C virus (HCV) infection are frequently co-infected with human immunodeficiency virus-1 (HIV-1), but it is still not clear whether HIV-1 worsens the natural history of hepatitis C. To investigate this, we conducted a multicentre observational study in 163 drug addicts with histological...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2000.00230.x

    authors: Romeo R,Rumi MG,Donato MF,Cargnel MA,Viganò P,Mondelli M,Cesana B,Colombo M

    更新日期:2000-07-01 00:00:00

  • Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B.

    abstract::The short-term prognosis of patients with severe acute exacerbation of chronic hepatitis B (CHB) leading to acute liver failure is extremely poor. We have reported the efficacy of corticosteroid in combination with nucleoside analogue in the early stages, but virological efficacy has not been documented. Our aim was t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12258

    authors: Yasui S,Fujiwara K,Nakamura M,Miyamura T,Yonemitsu Y,Mikata R,Arai M,Kanda T,Imazeki F,Oda S,Yokosuka O

    更新日期:2015-02-01 00:00:00

  • Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.

    abstract::Approximately 30% of patients with chronic HCV infection have persistently normal ALT levels. Although formerly referred to as 'healthy' or 'asymptomatic' HCV carriers, and thus historically excluded from antiviral treatment, it has now become clear that the majority of these patients have some degree of histological ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2011.01485.x

    authors: Puoti C,Guarisco R,Spilabotti L,Bellis L,Mitidieri Costanza O,Dell' Unto O,Elmo MG

    更新日期:2012-04-01 00:00:00

  • Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.

    abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1997.tb00180.x

    authors: Milich DR

    更新日期:1997-01-01 00:00:00